40
Participants
Start Date
August 1, 2017
Primary Completion Date
December 13, 2022
Study Completion Date
April 10, 2024
Ferric Carboxymaltose 50Mg/Ml Inj 15Ml
After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
Saline Solution for Injection
In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
Charité University Medicine Berlin, Berlin
Universitäres Herzzentrum Hamburg, Hamburg
University Medical Center Göttingen, Göttingen
Saarland University Medical Center, Homburg
Herzklinik Ulm, Ulm
Innere Medizin/Kardiologie, Nuremberg
Herzzentrum Dresden GmbH, Dresden
University of Göttingen
OTHER
Charite University, Berlin, Germany
OTHER